R3R-01 is under clinical development by River 3 Renal and currently in Phase II for Alport Syndrome. According to GlobalData, Phase II drugs for Alport Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how R3R-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

R3R-01 overview

R3R-01 is under development for the treatment of Alport syndrome and focal segmental glomerulosclerosis. It is administered through oral route. 

River 3 Renal overview

River 3 Renal is engaged in offering various pharmaceutical and healthcare related services, solutions and end products for its customers. The company is headquartered in New York, the US.

For a complete picture of R3R-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.